Clinical trials: Gram-negative Bacteremia
Salmonella Typhi Infection
Understanding How Salmonella Typhi Infects Humans (Bottlenecks)
Typhoid fever is an infection caused by the bacteria Salmonella Typhi (S. Typhi). S. Typhi causes disease principally in developing countries where communities do not have access to safe water or adequate sanitation.
- Trial name
- NCT03889067
- Testing
- Salmonella Typhi challenge
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Gram Negative Pneumonia, Gram-Negative Bacterial Infections
Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV
This study is designed to evaluate the clinical and antibacterial efficacy, safety and pharmacokinetics of the drug Fluorothiazinone compared to placebo to prevent nosocomial gram-negative bacterial infections with participation…
- Conditions
- Gram Negative Pneumonia, Gram-Negative Bacterial Infections, Bacteremia Caused by Gram-Negative Bacteria
- Trial name
- NCT06135350
- Testing
- Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day
- Where
- 2 sites in Russia
- Volunteers
- 234 people
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Bacteremia Sepsis
Resistell Phenotech AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia
The aim of this study is to assess the sensitivity, specificity, and accuracy of the Resistell Phenotech device in testing antibiotic susceptibility of Gram-negative bacteria (i.e., E. coli or K.
- Trial name
- PHENOTECH-1 (NCT05613322)
- Testing
- Resistell Phenotech
- Where
- 3 sites in Austria, Spain and 1 more
- Volunteers
- 246 people
- Sponsor
- Resistell AG
Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
Antimicrobial resistance is a major global problem, particularly in hospital-acquired infections (HAIs). Gram-negative bacilli (GNB), including Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, are among the…
- Conditions
- Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection, Severe Infection, Pseudomonas Aeruginosa
- Trial name
- OPTIMISE (NCT05210387)
- Testing
- Duration of therapy
- Where
- 29 sites in Brazil
- Volunteers
- 107 people
- Sponsor
- Hospital Moinhos de Vento
Klebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia
A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).
Klebsiella pneumonia, inhabitant of the digestive tract, is a frequent nosocomial pathogen. It is currently the fourth most common cause of pneumonia and fifth most common cause of bacteremia in intensive care patients (1-3).
- Trial name
- NCT01266499
- Testing
- Colistin (Polymyxin E) 100mg x 4/d, both medications, will not receive PO treatment
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Rambam Health Care Campus
Gram-negative Bacteremia
BALANCE+ Vanguard Phase
The goal of the BALANCE+ clinical trial is to transform random care to randomized care for patients with Gram negative bloodstream infections to inform best treatment approaches and optimize outcomes.
- Trial name
- BALANCE+ (NCT05893147)
- Testing
- De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement
- Where
- 10 sites in Canada
- Volunteers
- 174 people
- Sponsor
- Sunnybrook Health Sciences Centre
Allogeneic or Autologous HSCT
Gram-negative Bacteremia in HSCT Recipients
A significant increase in resistant bacteria emerging in HSCT recipients. For example, 25% - 42% of all enterobacteriaceae produce extended spectrum beta-lactamases; 8 - 72% of Pseudomonas aeruginosa are resistant to at least one…
- Trial name
- GNB (NCT02257931)
- Where
- 10 sites in Belgium, China and 7 more
- Volunteers
- 591 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Gram-negative Bacteremia, Intensive Care Patients
Impact of Real-time MIC (Minimum Inhibitory Concentration) Reporting (<6 Hours) on β-lactam Prescription in Cases of Gram-negative Bacilli Bacteremia in ICU Patients in Real-life Settings
Evaluate the impact of rapid, real-time (4 to 6 h) MIC reporting compared with the standard method (=diffusion antibiotic susceptibility testing) (18 to 24 h) on β-lactam prescribing in terms of the choice of molecule by the…
- Trial name
- CMIBActRéa (NCT07202377)
- Testing
- SPECIFIC REVEAL® Rapid AST system, antibiotic susceptibility testing on agar medium
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Escherichia Coli Bacteremia, Klebsiella Bacteraemia
Switch to Oral Antibiotics in Gram-negative Bacteremia
Eligible subjects will be those age 18 years or more with mono-microbial blood stream infection caused by E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, or Proteus species, who have…
- Conditions
- Escherichia Coli Bacteremia, Klebsiella Bacteraemia, Enterobacter Bacteraemia, Serratia Bacteraemia
- Trial name
- SOAB (NCT04146922)
- Testing
- Step down to oral antimicrobial therapy, IV antimicrobial therapy
- Where
- 7 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 176 people
- Sponsor
- Hamad Medical Corporation
Gram-Negative Bacterial Infections
Gram Negative Bacteremia, Risk Factors for Failure of Therapy
The aims of this study are to: Determine the risk factors for multidrug resistance in bloodstream isolates of Gram negative bacilli Determine the mechanisms of multidrug resistance in bloodstream isolates of Gram negative bacilli…
- Trial name
- NCT00177957
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- University of Pittsburgh
Beta-lactamase Extended Spectrum, E. Coli, Elderly, Mortality, Risk Factor
The Association Between Advancing Age and Mortality at 30 Days in Patients With Bacteremia E. Coli Beta-lactamase Phenotype Extended Spectrum RC15_0421
In the US and Europe, bacteremia are ranked the 7th leading cause of death from all causes. E. coli is one of the main microorganism involved, responsible for 30% to 45% of bacteremia. In Europe, bacteremia E.
- Trial name
- MoBaCo (NCT02847065)
- Where
- France
- Volunteers
- 144 people
- Sponsor
- Nantes University Hospital
Bacteremia Caused by Gram-Negative Bacteria, Bacterial Pneumonia
A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
This is a retrospective, observational, post-marketing study to evaluate the clinical response, microbiological response, mortality, and safety of intravenous polymyxin B and colistin methanesulfonate in patients with…
- Trial name
- NCT06966284
- Where
- Taiwan
- Volunteers
- 480 people
- Sponsor
- TTY Biopharm
Enterobacteriaceae Infections, Bloodstream Infection
Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae
The antimicrobial crisis is a real problem. Infections produced by multiresistant bacteria are becoming more and more frequent, and available antimicrobial agents are usually scarce.
- Trial name
- SHORTEN (NCT02400268)
- Testing
- 7 days course of antibiotic treatment, 14 days course of antibiotic treatment
- Where
- 4 sites in Spain
- Volunteers
- 238 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Bacteremia
T2 and SeptiCyte RAPID Duration Project
Infection with bacteria and other germs in the blood can be deadly. How long germs stay in the blood is important for two reasons.
- Trial name
- NCT04821661
- Where
- 3 sites in Australia
- Volunteers
- 102 people
- Sponsor
- The University of Queensland
Gram-negative Bacteraemia
Early Oral Switch for Uncomplicated Gram-negative Bacteraemia
Current management of uncomplicated Gram-negative bacteraemia entails prolong intravenous (IV) antibiotic therapy with limited evidence to guide oral conversion.
- Trial name
- INVEST (NCT05199324)
- Testing
- Oral fluoroquinolones (most commonly, ciprofloxacin) or oral trimethoprim-sulfamethoxazole, Standard of care intravenous antibiotics (e.g. ceftriaxone, cefazolin)
- Where
- 25 sites in Australia, Greece and 9 more
- Volunteers
- 720 people
- Sponsor
- Tan Tock Seng Hospital
Sepsis, Bacteremia
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by…
- Trial name
- CEFPK/PD (NCT00609375)
- Testing
- cefepime
- Where
- 7 sites in Colombia
- Volunteers
- 30 people
- Sponsor
- Javeriana University